Autoimmune Disease: Mechanisms, Triggers, and Treatment

80% of Autoimmune Patients Are Female. No One Fully Knows Why.

More than 80 recognized autoimmune diseases collectively affect approximately 50 million Americans — roughly 15% of the population. Women account for approximately 80% of autoimmune disease cases overall, though the ratio varies by condition: multiple sclerosis affects women at 3:1, lupus at 9:1, Hashimoto's thyroiditis at 7:1. Rheumatoid arthritis (RA) affects women at 3:1, while ankylosing spondylitis reverses the pattern, affecting men more commonly. This sex disparity remains one of the most intriguing unsolved puzzles in medicine, implicating X chromosome dosage, hormonal differences (estrogen tends to upregulate immune responses), and microbiome composition.

What Autoimmunity Means

In healthy individuals, the immune system learns to distinguish "self" from "non-self" through a process called central tolerance, occurring primarily in the thymus (for T cells) and bone marrow (for B cells). Immune cells that react strongly against self-proteins are deleted or suppressed. Autoimmune disease results when this self-tolerance breaks down, and the immune system mounts an attack against the body's own tissues.

Mechanisms of Autoimmunity

No single mechanism explains all autoimmune diseases, but several overlapping processes have been identified.

Molecular mimicry occurs when a foreign antigen — typically from a pathogen — is structurally similar to a self-protein, causing immune responses generated against the infection to cross-react with host tissue. The canonical example is rheumatic fever: antibodies generated against Group A Streptococcus cross-react with cardiac valve proteins, causing rheumatic heart disease. More recently, molecular mimicry has been implicated in Type 1 diabetes (cow's milk protein vs. beta cell antigen), narcolepsy (H1N1 influenza antigen vs. hypocretin receptor), and some post-COVID neurological conditions.

Loss of peripheral tolerance refers to the failure of mechanisms that suppress self-reactive T and B cells that escaped central tolerance. Regulatory T cells (Tregs), characterized by the FoxP3 transcription factor, normally suppress self-reactive lymphocytes. Genetic defects in FoxP3 cause IPEX syndrome — a severe, often fatal multi-organ autoimmune disease seen in infants.

• Defective Treg function has been documented in multiple sclerosis, systemic lupus erythematosus, and type 1 diabetes
• Bystander activation: during infection, innate immune activation (cytokine release) can inappropriately activate self-reactive T cells that were previously dormant
• Epitope spreading: an initial autoimmune attack exposes cryptic self-antigens not previously presented to the immune system, broadening the autoimmune response over time
• Neutrophil extracellular traps (NETs): structures released by dying neutrophils expose nuclear antigens, driving anti-nuclear antibody production in lupus

Genetic Predisposition

The HLA (human leukocyte antigen) gene complex on chromosome 6 is the strongest genetic contributor to autoimmune risk. Different HLA alleles confer risk for different conditions: HLA-B27 and ankylosing spondylitis, HLA-DR4 and rheumatoid arthritis, HLA-DQ2/DQ8 and celiac disease. However, HLA alone is insufficient — monozygotic twin concordance rates are 25–60% for most autoimmune diseases, confirming that environmental factors are essential co-triggers.

The Hygiene Hypothesis and Epidemiology

Autoimmune disease incidence has risen sharply in industrialized countries over the past 50 years — far too quickly to be explained by genetics alone. The hygiene hypothesis, proposed by epidemiologist David Strachan in 1989 (initially for allergies), proposes that reduced exposure to microorganisms in childhood leads to immune dysregulation. The "old friends" hypothesis (Rook, 2003) refined this: it is not "dirtiness" per se but the loss of co-evolved microbial organisms — helminths, diverse commensal bacteria — that previously calibrated the immune system's regulatory pathways.

The Biologics Revolution

Until the late 1990s, autoimmune treatment relied on broad immunosuppressants: corticosteroids, methotrexate, azathioprine. These suppressed the entire immune system, treating the disease while exposing patients to infection risk and organ toxicity. Biologics — targeted protein-based therapies — transformed treatment by blocking specific pathways.

• TNF inhibitors (etanercept, adalimumab, infliximab): first approved in 1998–2002; transformed outcomes in RA, psoriasis, Crohn's; now the world's top-selling drug class
• IL-17 inhibitors (secukinumab, ixekizumab): highly effective in ankylosing spondylitis and psoriatic arthritis; superior to TNF inhibitors for axial disease
• IL-6 inhibitors (tocilizumab, sarilumab): effective in RA and giant cell arteritis; also used in cytokine storm syndrome (COVID-19)
• B-cell depletion (rituximab): targets CD20 on B cells; first-line for many vasculitides and refractory RA
• JAK inhibitors (tofacitinib, baricitinib, upadacitinib): oral small molecules blocking intracellular signaling; treat RA, ulcerative colitis, atopic dermatitis

This article is for informational purposes only. Consult a qualified healthcare professional.